The molecular size bomb was devised by researchers at the Massachusetts Institute of Technology.

The researchers believe that this new approach to drug delivery, using existing drugs and materials could have a similar impact in humans. They also believe it may be adapted to function for other types of cancer and illnesses also to test drug combinations. Sasisekharan says they have already been in a position to show, that the technique, decreases the toxicity of the drugs definitely, and increases their efficacy. The findings are reported in the research journal Nature.. Amazing ‘smart bomb’ medicine zaps cancer cellular material in mice without damaging healthy cells Scientists say they are suffering from an anti-cancer ‘bomb’ that includes a similar behavior to a Trojan horse.Centered on Targeting Cancer Fat burning capacity Major Endpoint Met in Intergroupe Francophone du Myelome Phase III Study Analyzing Treatment with Continuous REVLIMID in Individuals with Multiple Myeloma Pursuing Autologous Stem Cell Transplant Initiated MDS-005 Stage III Trial Evaluating REVLIMID in Low/Int-1 non-del5q Myelodysplastic Syndromes Stage I Study of PDA-001, Celgene Cellular Therapeutics’ Immunomodulatory Therapy, Met Main Endpoint of Basic safety and Demonstrated Encouraging Clinical Benefit 2010 Selected Corporate Goals Expand Celgene Product Approvals, Reimbursements and Global Marketplace Share Submit REVLIMID Newly Diagnosed Multiple Myeloma Regulatory Filings with European Medicines Agency and Meals and Medication Administration Gain Marketing Authorization and Launch REVLIMID in Japan for Multiple Myeloma Full Enrollment of MM-020, a Phase III Trial> REVLIMID Data from IFM 2005-02, CALGB-100104, and MM-015 Trials to be Presented at Main Medical Meetings Comprehensive U.S.